Press coverage about Endologix (NASDAQ:ELGX) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endologix earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.1550646276536 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Critical Contrast: Endologix (ELGX) and Its Competitors (americanbankingnews.com)
- Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Critical Comparison: Endologix (ELGX) vs. Its Rivals (americanbankingnews.com)
- Reviewing Endologix (ELGX) & The Competition (americanbankingnews.com)
- Contrasting Endologix (ELGX) & Its Peers (americanbankingnews.com)
A number of analysts have commented on the company. Royal Bank of Canada reduced their price objective on Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 8th. ValuEngine cut Endologix from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Stifel Nicolaus decreased their price objective on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $5.00 price objective on shares of Endologix in a research note on Monday, October 9th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.41.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.